Acurx Pharmaceuticals, Inc. (ACXP) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 3 Buy.
Analysts estimate Earnings Per Share (EPS) of $-16.80 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-872.54 vs est $-16.80 (missed -5093.7%). 2025: actual $-5.32 vs est $-6.05 (beat +12%). Analyst accuracy: 44%.
ACXP Analyst Ratings
Buy
Based on 3 analysts giving stock ratings to Acurx Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — ACXP
44%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$872.54
vs Est –$16.80
▼ 98.1% off
2025
Actual –$5.32
vs Est –$6.05
▲ 13.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ACXP
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
